[{"id":"1b4e994d-52e1-4f2a-9230-cf391cb47aea","acronym":"NCI-2023-03572","url":"https://clinicaltrials.gov/study/NCT06034470","created_at":"2023-09-13T14:09:48.343Z","updated_at":"2025-02-25T17:02:50.246Z","phase":"Phase 1","brief_title":"Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms","source_id_and_acronym":"NCT06034470 - NCI-2023-03572","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" IL3RA","pipe":" | ","alterations":" Chr t(15;17)","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • fludarabine IV • pivekimab sunirine (PVEK) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-03"},{"id":"268eae36-cdca-45ae-8506-36b3e8cbd7f6","acronym":"BLAST MRD AML-2","url":"https://clinicaltrials.gov/study/NCT04284787","created_at":"2024-03-22T03:46:14.077Z","updated_at":"2025-02-25T17:00:27.213Z","phase":"Phase 2","brief_title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04284787 - BLAST MRD AML-2","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD8 • PD-1 • IFNG • GZMB • FOXP3","pipe":" | ","alterations":" PD-L1 expression • Chr t(15;17)","tags":["PD-L1 • CD8 • PD-1 • IFNG • GZMB • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Venclexta (venetoclax) • azacitidine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/16/2021","start_date":" 02/16/2021","primary_txt":" Primary completion: 06/05/2023","primary_completion_date":" 06/05/2023","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-03"},{"id":"8e4c392a-1d29-432d-a4da-6bb8e1258676","acronym":"AG120-221-C-001","url":"https://clinicaltrials.gov/study/NCT02632708","created_at":"2021-01-17T17:12:58.212Z","updated_at":"2025-02-25T14:36:02.501Z","phase":"Phase 1","brief_title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","source_id_and_acronym":"NCT02632708 - AG120-221-C-001","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation","tags":["IDH1 • IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • Tibsovo (ivosidenib) • daunorubicin • Idhifa (enasidenib) • idarubicin hydrochloride • mitoxantrone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 12/31/2015","start_date":" 12/31/2015","primary_txt":" Primary completion: 12/13/2018","primary_completion_date":" 12/13/2018","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-07-25"},{"id":"5f9fcf16-f9cb-4521-b187-17cb8a4a4f38","acronym":"2102-HEM-101","url":"https://clinicaltrials.gov/study/NCT02719574","created_at":"2021-01-17T17:25:33.100Z","updated_at":"2024-07-02T16:35:10.352Z","phase":"Phase 1/2","brief_title":"Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation","source_id_and_acronym":"NCT02719574 - 2102-HEM-101","lead_sponsor":"Forma Therapeutics, Inc.","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132 • Chr t(15;17)","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132 • Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • Rezlidhia (olutasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 336","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 12/28/2023","primary_completion_date":" 12/28/2023","study_txt":" Completion: 01/24/2024","study_completion_date":" 01/24/2024","last_update_posted":"2024-04-10"},{"id":"e5940e7b-30fd-4553-89ee-3676c7d30b8b","acronym":"A2408","url":"https://clinicaltrials.gov/study/NCT03379727","created_at":"2021-01-17T17:21:47.746Z","updated_at":"2024-07-02T16:35:17.043Z","phase":"Phase 3","brief_title":"Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.","source_id_and_acronym":"NCT03379727 - A2408","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • Chr t(15;17)","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • daunorubicin • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 301","initiation":"Initiation: 02/13/2018","start_date":" 02/13/2018","primary_txt":" Primary completion: 07/09/2021","primary_completion_date":" 07/09/2021","study_txt":" Completion: 07/09/2021","study_completion_date":" 07/09/2021","last_update_posted":"2024-02-29"},{"id":"98b146c5-bd25-418a-a86a-b48aaa091bb5","acronym":"AG-221-C-001","url":"https://clinicaltrials.gov/study/NCT01915498","created_at":"2021-01-17T17:36:57.841Z","updated_at":"2024-07-02T16:35:19.804Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation","source_id_and_acronym":"NCT01915498 - AG-221-C-001","lead_sponsor":"Celgene","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 345","initiation":"Initiation: 08/27/2013","start_date":" 08/27/2013","primary_txt":" Primary completion: 07/25/2019","primary_completion_date":" 07/25/2019","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2024-02-12"},{"id":"516b31f5-466c-4410-8cae-2fcf87e0c0c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01746849","created_at":"2021-01-18T07:39:24.877Z","updated_at":"2024-07-02T16:35:24.333Z","phase":"Phase 2","brief_title":"Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT01746849","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34 • CD4","pipe":" | ","alterations":" Chr t(15;17)","tags":["CD34 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Firmagon (degarelix) • thiotepa • leuprolide acetate for depot suspension • Kepivance (palifermin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-05"},{"id":"d3fbe9fc-cb0c-4ea4-a0c8-0aaa88366b82","acronym":"TUD-APOLLO-064","url":"https://clinicaltrials.gov/study/NCT02688140","created_at":"2022-03-24T01:54:02.216Z","updated_at":"2024-07-02T16:35:30.678Z","phase":"Phase 3","brief_title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT02688140 - TUD-APOLLO-064","lead_sponsor":"Technische Universität Dresden","biomarkers":" PML","pipe":" | ","alterations":" PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • mitoxantrone • arsenic trioxide • mercaptopurine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-11-02"},{"id":"a33ded0a-8d2b-4dec-8eb6-bc89ee154d4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01420926","created_at":"2021-01-18T05:51:36.898Z","updated_at":"2024-07-02T16:35:54.587Z","phase":"Phase 2","brief_title":"Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT01420926","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • RUNX1 • PML","pipe":" | ","alterations":" FLT3 mutation • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion","tags":["FLT3 • RUNX1 • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • azacitidine • decitabine"],"overall_status":"Completed","enrollment":" Enrollment 165","initiation":"Initiation: 11/16/2011","start_date":" 11/16/2011","primary_txt":" Primary completion: 06/05/2016","primary_completion_date":" 06/05/2016","study_txt":" Completion: 04/01/2021","study_completion_date":" 04/01/2021","last_update_posted":"2023-02-28"},{"id":"524a0eb6-071e-4968-ae8c-51db52817873","acronym":"","url":"https://clinicaltrials.gov/study/NCT00492856","created_at":"2021-01-18T01:45:43.940Z","updated_at":"2024-07-02T16:35:57.935Z","phase":"Phase 3","brief_title":"S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT00492856","lead_sponsor":"Southwest Oncology Group","biomarkers":" PML","pipe":" | ","alterations":" Chr t(15;17)","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • Mylotarg (gemtuzumab ozogamicin) • mercaptopurine"],"overall_status":"Completed","enrollment":" Enrollment 105","initiation":"Initiation: 06/01/2007","start_date":" 06/01/2007","primary_txt":" Primary completion: 12/01/2013","primary_completion_date":" 12/01/2013","study_txt":" Completion: 05/04/2016","study_completion_date":" 05/04/2016","last_update_posted":"2023-01-10"},{"id":"a38ba7d6-a220-4bff-9bf0-90309625cd62","acronym":"APL0406","url":"https://clinicaltrials.gov/study/NCT00482833","created_at":"2021-03-29T12:16:38.586Z","updated_at":"2024-07-02T16:36:02.654Z","phase":"Phase 3","brief_title":"Phase III Trial in Acute Promyelocytic Leukemia Patients","source_id_and_acronym":"NCT00482833 - APL0406","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" PML","pipe":" | ","alterations":" PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e idarubicin hydrochloride • arsenic trioxide • mercaptopurine"],"overall_status":"Completed","enrollment":" Enrollment 276","initiation":"Initiation: 08/01/2007","start_date":" 08/01/2007","primary_txt":" Primary completion: 09/01/2012","primary_completion_date":" 09/01/2012","study_txt":" Completion: 10/17/2019","study_completion_date":" 10/17/2019","last_update_posted":"2022-10-11"},{"id":"03f05543-0558-4406-af40-e682d4bba542","acronym":"","url":"https://clinicaltrials.gov/study/NCT01119066","created_at":"2021-01-18T04:26:17.749Z","updated_at":"2024-07-02T16:36:05.975Z","phase":"Phase 2","brief_title":"HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies","source_id_and_acronym":"NCT01119066","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":" | ","alterations":" Chr t(4;14) • Chr t(14;16) • Chr t(15;17)","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(4;14) • Chr t(14;16) • Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • clofarabine • melphalan • fludarabine IV • thiotepa • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 422","initiation":"Initiation: 05/03/2010","start_date":" 05/03/2010","primary_txt":" Primary completion: 03/30/2021","primary_completion_date":" 03/30/2021","study_txt":" Completion: 03/30/2021","study_completion_date":" 03/30/2021","last_update_posted":"2022-08-05"},{"id":"20f89bfd-19a7-41d7-824a-1d01ee002b27","acronym":"","url":"https://clinicaltrials.gov/study/NCT01253070","created_at":"2021-01-18T05:03:01.330Z","updated_at":"2024-07-02T16:36:06.069Z","phase":"Phase 2","brief_title":"Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT01253070","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • RUNX1","pipe":" | ","alterations":" FLT3 mutation • Chr t(15;17)","tags":["FLT3 • RUNX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • cytarabine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 10/31/2014","primary_completion_date":" 10/31/2014","study_txt":" Completion: 04/15/2021","study_completion_date":" 04/15/2021","last_update_posted":"2022-08-04"}]